Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26928520 | 0.90 | POLB (0.43) | CHEK2ROCK1GPR119POLBPIK3CD | |
| SCHEMBL4008769 | 0.89 | ROCK1 (0.56) | CHEK2ROCK1ROCK2KCNH2GPR119 | |
| SCHEMBL2507446 | 0.88 | GPR119 (0.51) | CHEK2ROCK1GPR119POLBPDE4B | |
| SCHEMBL4966168 | 0.87 | ROCK1 (0.52) | CHEK2ROCK1ROCK2KCNH2 | |
| SCHEMBL190408 | 0.84 | CHEK2 (0.51) | CHEK2GPR119PIK3CDPIK3CAPIK3CB | |
| SCHEMBL4005989 | 0.83 | CHEK2 (0.46) | CHEK2ROCK1ROCK2KCNH2GPR119 | |
| SCHEMBL4005985 | 0.83 | CHEK2 (0.46) | CHEK2ROCK1ROCK2KCNH2GPR119 | |
| SCHEMBL18318826 | 0.81 | CHEK2 (0.51) | CHEK2GPR119POLBPIK3CDPIK3CA | |
| SCHEMBL20281697 | 0.81 | CHEK2 (0.51) | CHEK2GPR119PIK3CDPIK3CAPIK3CB | |
| SCHEMBL21999105 | 0.80 | CHEK2 (0.53) | CHEK2GPR119PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963304-B2 | ISOQUINOLINE DERIVATIVES | MSD OSS BV (NL) | 2015-05-13 | — | — | EP | disclosed |
| US-7618985-B2 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| EP-1963304-B1 | ISOQUINOLINE DERIVATIVES | ORGANON NV (NL) | 2009-06-24 | — | — | EP | disclosed |
| EP-1963304-A1 | ISOQUINOLINE DERIVATIVES | N.V. Organon (NL) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065916-A1 | ISOQUINOLINE DERIVATIVES | N.V. ORGANON (NL) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135479-A1 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135479-A1 | Isoquinoline derivatives | ROCK1, ROCK2, RHOA | CHEK2 2515/4885ROCK1 1/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.